Delamanid | List of Frontiers open access articles

Clinical Trial

Published on 29 Sep 2025

Delamanid-containing regimens over 24 weeks for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis: preliminary results from a single center in a multicenter, prospective, observational study

in Pulmonary Medicine

Fuping Yang
Mingdan Yin
Xingmei Jiang
Xing Zhao
Xuemei An
Yan Liu
Yijia Yuan

Frontiers in Medicine

doi 10.3389/fmed.2025.1631030

2,121 views

Perspective

Published on 11 Dec 2017

Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant Tuberculosis

in Antimicrobials, Resistance and Chemotherapy

Divakar Sharma
Yogesh K. Dhuriya
Nirmala Deo
Deepa Bisht

Frontiers in Microbiology

doi 10.3389/fmicb.2017.02452

9,051 views
43 citations

Review

Published on 07 Oct 2021

Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis

in Antimicrobials, Resistance and Chemotherapy

Saeed Khoshnood
Elahe Taki
Nourkhoda Sadeghifard
Vahab Hassan Kaviar
Mohammad Hossein Haddadi
Zahra Farshadzadeh
Ebrahim Kouhsari
Mehdi Goudarzi
Mohsen Heidary

Frontiers in Microbiology

doi 10.3389/fmicb.2021.717045

16,802 views
55 citations

Review

Published on 13 Jun 2023

Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children

in Clinical and Diagnostic Microbiology and Immunology

Hanzhao Zhu
Xintong Zhou
Zengfang Zhuang
Lianju Li
Jing Bi
Kaixia Mi

Frontiers in Cellular and Infection Microbiology

doi 10.3389/fcimb.2023.1183597

11,212 views
17 citations

Original Research

Published on 21 Jan 2026

The microevolutionary trajectory of endemic multidrug-resistant tuberculosis strains in Portugal toward increased drug resistance levels and its clinical significance

in Antimicrobials, Resistance and Chemotherapy

Pedro Gomes
Paulo Paixão
Fernando Maltez
Laura Brum
Jody E. Phelan
Susana Campino
Taane G. Clark
Miguel Viveiros
Isabel Portugal
João Perdigão

Frontiers in Microbiology

doi 10.3389/fmicb.2025.1716549

1,176 views

Mini Review

Published on 26 Jan 2021

The Prospective Synergy of Antitubercular Drugs With NAD Biosynthesis Inhibitors

in Antimicrobials, Resistance and Chemotherapy

Kyle H. Rohde
Leonardo Sorci

Frontiers in Microbiology

doi 10.3389/fmicb.2020.634640

8,948 views
11 citations

Original Research

Published on 08 Nov 2022

Delamanid suppresses CXCL10 expression via regulation of JAK/STAT1 signaling and correlates with reduced inflammation in tuberculosis patients

in Microbial Immunology

Min Qiao
Shanshan Li
Jinfeng Yuan
Weicong Ren
Yuanyuan Shang
Wei Wang
Rongmei Liu
Fuzhen Zhang
Qing Li
Xiao Wu

Frontiers in Immunology

doi 10.3389/fimmu.2022.923492

5,254 views
13 citations

Original Research

Published on 24 Dec 2021

The Activities and Secretion of Cytokines Caused by Delamanid on Macrophages Infected by Multidrug-Resistant Mycobacterium tuberculosis Strains

in Molecular Innate Immunity

Xia-Li Lyu
Ting-Ting Lin
Jing-Tao Gao
Hong-Yan Jia
Chuan-Zhi Zhu
Zi-Hui Li
Jing Dong
Qi Sun
Wei Shu
Li-Ping Pan

Frontiers in Immunology

doi 10.3389/fimmu.2021.796677

4,132 views
4 citations

Original Research

Published on 15 Oct 2025

Mycobacterium tuberculosis genomic surveillance in Mexico. Characterization of variants in drug resistance and efflux pump genes

in Antimicrobials, Resistance and Chemotherapy

Néstor Alvarado-Peña
Marcela Muñoz Torrico
Luis Narváez-Díaz
Paulina M. Mejía-Ponce
Eduardo Becerril Vargas
Joaquín Zúñiga
Raquel Muñiz-Salazar
Rafael Laniado-Laborín
Cuauhtémoc Licona-Cassani
Xavier Soberón

Frontiers in Microbiology

doi 10.3389/fmicb.2025.1666838

3,367 views

Review

Published on 07 Oct 2022

Evolution of Mycobacterium tuberculosis drug resistance in the genomic era

in Molecular Bacterial Pathogenesis

Camus Nimmo
James Millard
Valwynne Faulkner
Johana Monteserin
Hannah Pugh
Eachan Oliver Johnson

Frontiers in Cellular and Infection Microbiology

doi 10.3389/fcimb.2022.954074

20,974 views
48 citations

Original Research

Accepted on 18 Feb 2026

Wild-type MIC Distribution and Evaluation of Epidemiological Cut-Offs of Second-line TB-drugs in Susceptible and MDR-TB Clinical Isolates from Chennai, India

in Antimicrobials, Resistance and Chemotherapy

Azger Dusthackeer
Mahizhaveni Balasubramanian
Sam Ebenezer Rajadas
Christy Rosaline Nirmal
Padmasini Elango
Kannan Thiruvengadam
Shainaba A Saadhali
Siva Kumar Shanmugam

Frontiers in Microbiology

Original Research

Published on 11 Feb 2025

Whole genomic analysis uncovers high genetic diversity of rifampicin-resistant Mycobacterium tuberculosis strains in Botswana

in Infectious Agents and Disease

Tuelo Mogashoa
Johannes Loubser
Ontlametse T. Choga
Justice Tresor Ngom
Wonderful T. Choga
Mpaphi B. Mbulawa
Tuduetso Molefi
One Stephen
Topo Makhondo
Kedumetse Seru

Frontiers in Microbiology

doi 10.3389/fmicb.2025.1535160

5,069 views
6 citations

Articles

Delamanid-containing regimens over 24 weeks for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis: preliminary results from a single center in a multicenter, prospective, observational study

Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant Tuberculosis

Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis

Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children

The microevolutionary trajectory of endemic multidrug-resistant tuberculosis strains in Portugal toward increased drug resistance levels and its clinical significance

The Prospective Synergy of Antitubercular Drugs With NAD Biosynthesis Inhibitors

Delamanid suppresses CXCL10 expression via regulation of JAK/STAT1 signaling and correlates with reduced inflammation in tuberculosis patients

The Activities and Secretion of Cytokines Caused by Delamanid on Macrophages Infected by Multidrug-Resistant Mycobacterium tuberculosis Strains

Mycobacterium tuberculosis genomic surveillance in Mexico. Characterization of variants in drug resistance and efflux pump genes

Evolution of Mycobacterium tuberculosis drug resistance in the genomic era

Wild-type MIC Distribution and Evaluation of Epidemiological Cut-Offs of Second-line TB-drugs in Susceptible and MDR-TB Clinical Isolates from Chennai, India

Whole genomic analysis uncovers high genetic diversity of rifampicin-resistant Mycobacterium tuberculosis strains in Botswana

Delamanid-containing regimens over 24 weeks for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis: preliminary results from a single center in a multicenter, prospective, observational study